世界の血液がん治療市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Blood Cancer Therapeutics Market 2021 by Company, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-107A12103 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、105ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料では、血液がん治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。血液がん治療の種類別市場規模（慢性骨髄性白血病（CML）、急性リンパ性白血病（ALL）、慢性リンパ性白血病（CLL）、急性骨髄性白血病（AML））、用途別市場規模（がん研究センター、がん病院、外科センター、クリニック）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・血液がん治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：AbbVie、AstraZeneca、Bristol-Myers Squibb、GlaxoSmithKline、Roche、Novartis、Boehringer Ingelheim、Pfizer、Sanofi ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：慢性骨髄性白血病（CML）、急性リンパ性白血病（ALL）、慢性リンパ性白血病（CLL）、急性骨髄性白血病（AML） ・用途別分析2016年-2026年：がん研究センター、がん病院、外科センター、クリニック ・血液がん治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・血液がん治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・血液がん治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・血液がん治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・血液がん治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Blood Cancer Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Blood Cancer Therapeutics size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Blood Cancer Therapeutics market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Blood Cancer Therapeutics market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Chronic Myeloid Leukemia (CML)
Acute Lymphocytic Leukemia (ALL)
Chronic Lymphocytic Leukemia (CLL)
Acute Myeloid Leukemia (AML)

Market segment by Application, can be divided into
Cancer Research Centers
Cancer Hospital
Surgical Centers
Clinics

Market segment by players, this report covers
AbbVie
AstraZeneca
Bristol-Myers Squibb
GlaxoSmithKline
Roche
Novartis
Boehringer Ingelheim
Pfizer
Sanofi

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

レポート目次

---

1 Market Overview
1.1 Product Overview and Scope of Blood Cancer Therapeutics
1.2 Classification of Blood Cancer Therapeutics by Type
1.2.1 Overview: Global Blood Cancer Therapeutics Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Blood Cancer Therapeutics Revenue Market Share by Type in 2020
1.2.3 Chronic Myeloid Leukemia (CML)
1.2.4 Acute Lymphocytic Leukemia (ALL)
1.2.5 Chronic Lymphocytic Leukemia (CLL)
1.2.6 Acute Myeloid Leukemia (AML)
1.3 Global Blood Cancer Therapeutics Market by Application
1.3.1 Overview: Global Blood Cancer Therapeutics Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Cancer Research Centers
1.3.3 Cancer Hospital
1.3.4 Surgical Centers
1.3.5 Clinics
1.4 Global Blood Cancer Therapeutics Market Size & Forecast
1.5 Global Blood Cancer Therapeutics Market Size and Forecast by Region
1.5.1 Global Blood Cancer Therapeutics Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Blood Cancer Therapeutics Market Size by Region, (2016-2021)
1.5.3 North America Blood Cancer Therapeutics Market Size and Prospect (2016-2026)
1.5.4 Europe Blood Cancer Therapeutics Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Blood Cancer Therapeutics Market Size and Prospect (2016-2026)
1.5.6 South America Blood Cancer Therapeutics Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Blood Cancer Therapeutics Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Blood Cancer Therapeutics Market Drivers
1.6.2 Blood Cancer Therapeutics Market Restraints
1.6.3 Blood Cancer Therapeutics Trends Analysis
2 Company Profiles
2.1 AbbVie
2.1.1 AbbVie Details
2.1.2 AbbVie Major Business
2.1.3 AbbVie Blood Cancer Therapeutics Product and Solutions
2.1.4 AbbVie Blood Cancer Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 AbbVie Recent Developments and Future Plans
2.2 AstraZeneca
2.2.1 AstraZeneca Details
2.2.2 AstraZeneca Major Business
2.2.3 AstraZeneca Blood Cancer Therapeutics Product and Solutions
2.2.4 AstraZeneca Blood Cancer Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 AstraZeneca Recent Developments and Future Plans
2.3 Bristol-Myers Squibb
2.3.1 Bristol-Myers Squibb Details
2.3.2 Bristol-Myers Squibb Major Business
2.3.3 Bristol-Myers Squibb Blood Cancer Therapeutics Product and Solutions
2.3.4 Bristol-Myers Squibb Blood Cancer Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.4 GlaxoSmithKline
2.4.1 GlaxoSmithKline Details
2.4.2 GlaxoSmithKline Major Business
2.4.3 GlaxoSmithKline Blood Cancer Therapeutics Product and Solutions
2.4.4 GlaxoSmithKline Blood Cancer Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 GlaxoSmithKline Recent Developments and Future Plans
2.5 Roche
2.5.1 Roche Details
2.5.2 Roche Major Business
2.5.3 Roche Blood Cancer Therapeutics Product and Solutions
2.5.4 Roche Blood Cancer Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Roche Recent Developments and Future Plans
2.6 Novartis
2.6.1 Novartis Details
2.6.2 Novartis Major Business
2.6.3 Novartis Blood Cancer Therapeutics Product and Solutions
2.6.4 Novartis Blood Cancer Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Novartis Recent Developments and Future Plans
2.7 Boehringer Ingelheim
2.7.1 Boehringer Ingelheim Details
2.7.2 Boehringer Ingelheim Major Business
2.7.3 Boehringer Ingelheim Blood Cancer Therapeutics Product and Solutions
2.7.4 Boehringer Ingelheim Blood Cancer Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Boehringer Ingelheim Recent Developments and Future Plans
2.8 Pfizer
2.8.1 Pfizer Details
2.8.2 Pfizer Major Business
2.8.3 Pfizer Blood Cancer Therapeutics Product and Solutions
2.8.4 Pfizer Blood Cancer Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Pfizer Recent Developments and Future Plans
2.9 Sanofi
2.9.1 Sanofi Details
2.9.2 Sanofi Major Business
2.9.3 Sanofi Blood Cancer Therapeutics Product and Solutions
2.9.4 Sanofi Blood Cancer Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Sanofi Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Blood Cancer Therapeutics Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Blood Cancer Therapeutics Players Market Share
3.2.2 Top 10 Blood Cancer Therapeutics Players Market Share
3.2.3 Market Competition Trend
3.3 Blood Cancer Therapeutics Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Blood Cancer Therapeutics Revenue and Market Share by Type (2016-2021)
4.2 Global Blood Cancer Therapeutics Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Blood Cancer Therapeutics Revenue Market Share by Application (2016-2021)
5.2 Blood Cancer Therapeutics Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Blood Cancer Therapeutics Revenue by Type (2016-2026)
6.2 North America Blood Cancer Therapeutics Revenue by Application (2016-2026)
6.3 North America Blood Cancer Therapeutics Market Size by Country
6.3.1 North America Blood Cancer Therapeutics Revenue by Country (2016-2026)
6.3.2 United States Blood Cancer Therapeutics Market Size and Forecast (2016-2026)
6.3.3 Canada Blood Cancer Therapeutics Market Size and Forecast (2016-2026)
6.3.4 Mexico Blood Cancer Therapeutics Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Blood Cancer Therapeutics Revenue by Type (2016-2026)
7.2 Europe Blood Cancer Therapeutics Revenue by Application (2016-2026)
7.3 Europe Blood Cancer Therapeutics Market Size by Country
7.3.1 Europe Blood Cancer Therapeutics Revenue by Country (2016-2026)
7.3.2 Germany Blood Cancer Therapeutics Market Size and Forecast (2016-2026)
7.3.3 France Blood Cancer Therapeutics Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Blood Cancer Therapeutics Market Size and Forecast (2016-2026)
7.3.5 Russia Blood Cancer Therapeutics Market Size and Forecast (2016-2026)
7.3.6 Italy Blood Cancer Therapeutics Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Blood Cancer Therapeutics Revenue by Type (2016-2026)
8.2 Asia-Pacific Blood Cancer Therapeutics Revenue by Application (2016-2026)
8.3 Asia-Pacific Blood Cancer Therapeutics Market Size by Region
8.3.1 Asia-Pacific Blood Cancer Therapeutics Revenue by Region (2016-2026)
8.3.2 China Blood Cancer Therapeutics Market Size and Forecast (2016-2026)
8.3.3 Japan Blood Cancer Therapeutics Market Size and Forecast (2016-2026)
8.3.4 South Korea Blood Cancer Therapeutics Market Size and Forecast (2016-2026)
8.3.5 India Blood Cancer Therapeutics Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Blood Cancer Therapeutics Market Size and Forecast (2016-2026)
8.3.7 Australia Blood Cancer Therapeutics Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Blood Cancer Therapeutics Revenue by Type (2016-2026)
9.2 South America Blood Cancer Therapeutics Revenue by Application (2016-2026)
9.3 South America Blood Cancer Therapeutics Market Size by Country
9.3.1 South America Blood Cancer Therapeutics Revenue by Country (2016-2026)
9.3.2 Brazil Blood Cancer Therapeutics Market Size and Forecast (2016-2026)
9.3.3 Argentina Blood Cancer Therapeutics Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Blood Cancer Therapeutics Revenue by Type (2016-2026)
10.2 Middle East & Africa Blood Cancer Therapeutics Revenue by Application (2016-2026)
10.3 Middle East & Africa Blood Cancer Therapeutics Market Size by Country
10.3.1 Middle East & Africa Blood Cancer Therapeutics Revenue by Country (2016-2026)
10.3.2 Turkey Blood Cancer Therapeutics Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Blood Cancer Therapeutics Market Size and Forecast (2016-2026)
10.3.4 UAE Blood Cancer Therapeutics Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Blood Cancer Therapeutics Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Blood Cancer Therapeutics Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Blood Cancer Therapeutics Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Blood Cancer Therapeutics Revenue (USD Million) by Region (2016-2021)
Table 5. Global Blood Cancer Therapeutics Revenue Market Share by Region (2021-2026)
Table 6. AbbVie Corporate Information, Head Office, and Major Competitors
Table 7. AbbVie Major Business
Table 8. AbbVie Blood Cancer Therapeutics Product and Solutions
Table 9. AbbVie Blood Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 11. AstraZeneca Major Business
Table 12. AstraZeneca Blood Cancer Therapeutics Product and Solutions
Table 13. AstraZeneca Blood Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors
Table 15. Bristol-Myers Squibb Major Business
Table 16. Bristol-Myers Squibb Blood Cancer Therapeutics Product and Solutions
Table 17. Bristol-Myers Squibb Blood Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors
Table 19. GlaxoSmithKline Major Business
Table 20. GlaxoSmithKline Blood Cancer Therapeutics Product and Solutions
Table 21. GlaxoSmithKline Blood Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Roche Corporate Information, Head Office, and Major Competitors
Table 23. Roche Major Business
Table 24. Roche Blood Cancer Therapeutics Product and Solutions
Table 25. Roche Blood Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Novartis Corporate Information, Head Office, and Major Competitors
Table 27. Novartis Major Business
Table 28. Novartis Blood Cancer Therapeutics Product and Solutions
Table 29. Novartis Blood Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Boehringer Ingelheim Corporate Information, Head Office, and Major Competitors
Table 31. Boehringer Ingelheim Major Business
Table 32. Boehringer Ingelheim Blood Cancer Therapeutics Product and Solutions
Table 33. Boehringer Ingelheim Blood Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Pfizer Corporate Information, Head Office, and Major Competitors
Table 35. Pfizer Major Business
Table 36. Pfizer Blood Cancer Therapeutics Product and Solutions
Table 37. Pfizer Blood Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Sanofi Corporate Information, Head Office, and Major Competitors
Table 39. Sanofi Major Business
Table 40. Sanofi Blood Cancer Therapeutics Product and Solutions
Table 41. Sanofi Blood Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Global Blood Cancer Therapeutics Revenue (USD Million) by Players (2019-2021)
Table 43. Global Blood Cancer Therapeutics Revenue Share by Players (2019-2021)
Table 44. Breakdown of Blood Cancer Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 45. Blood Cancer Therapeutics Players Head Office, Products and Services Provided
Table 46. Blood Cancer Therapeutics Mergers & Acquisitions in the Past Five Years
Table 47. Blood Cancer Therapeutics New Entrants and Expansion Plans
Table 48. Global Blood Cancer Therapeutics Revenue (USD Million) by Type (2016-2021)
Table 49. Global Blood Cancer Therapeutics Revenue Share by Type (2016-2021)
Table 50. Global Blood Cancer Therapeutics Revenue Forecast by Type (2021-2026)
Table 51. Global Blood Cancer Therapeutics Revenue by Application (2016-2021)
Table 52. Global Blood Cancer Therapeutics Revenue Forecast by Application (2021-2026)
Table 53. North America Blood Cancer Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 54. North America Blood Cancer Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 55. North America Blood Cancer Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 56. North America Blood Cancer Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 57. North America Blood Cancer Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 58. North America Blood Cancer Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 59. Europe Blood Cancer Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 60. Europe Blood Cancer Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 61. Europe Blood Cancer Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 62. Europe Blood Cancer Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 63. Europe Blood Cancer Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 64. Europe Blood Cancer Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 65. Asia-Pacific Blood Cancer Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 66. Asia-Pacific Blood Cancer Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 67. Asia-Pacific Blood Cancer Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 68. Asia-Pacific Blood Cancer Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 69. Asia-Pacific Blood Cancer Therapeutics Revenue by Region (2016-2021) & (USD Million)
Table 70. Asia-Pacific Blood Cancer Therapeutics Revenue by Region (2021-2026) & (USD Million)
Table 71. South America Blood Cancer Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 72. South America Blood Cancer Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 73. South America Blood Cancer Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 74. South America Blood Cancer Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 75. South America Blood Cancer Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 76. South America Blood Cancer Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 77. Middle East & Africa Blood Cancer Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 78. Middle East & Africa Blood Cancer Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 79. Middle East & Africa Blood Cancer Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 80. Middle East & Africa Blood Cancer Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 81. Middle East & Africa Blood Cancer Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 82. Middle East & Africa Blood Cancer Therapeutics Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Blood Cancer Therapeutics Picture
Figure 2. Global Blood Cancer Therapeutics Revenue Market Share by Type in 2020
Figure 3. Chronic Myeloid Leukemia (CML)
Figure 4. Acute Lymphocytic Leukemia (ALL)
Figure 5. Chronic Lymphocytic Leukemia (CLL)
Figure 6. Acute Myeloid Leukemia (AML)
Figure 7. Blood Cancer Therapeutics Revenue Market Share by Application in 2020
Figure 8. Cancer Research Centers Picture
Figure 9. Cancer Hospital Picture
Figure 10. Surgical Centers Picture
Figure 11. Clinics Picture
Figure 12. Global Blood Cancer Therapeutics Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 13. Global Blood Cancer Therapeutics Revenue and Forecast (2016-2026) & (USD Million)
Figure 14. Global Blood Cancer Therapeutics Revenue Market Share by Region (2016-2026)
Figure 15. Global Blood Cancer Therapeutics Revenue Market Share by Region in 2020
Figure 16. North America Blood Cancer Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Europe Blood Cancer Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Asia-Pacific Blood Cancer Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. South America Blood Cancer Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Middle East and Africa Blood Cancer Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Blood Cancer Therapeutics Market Drivers
Figure 22. Blood Cancer Therapeutics Market Restraints
Figure 23. Blood Cancer Therapeutics Market Trends
Figure 24. AbbVie Recent Developments and Future Plans
Figure 25. AstraZeneca Recent Developments and Future Plans
Figure 26. Bristol-Myers Squibb Recent Developments and Future Plans
Figure 27. GlaxoSmithKline Recent Developments and Future Plans
Figure 28. Roche Recent Developments and Future Plans
Figure 29. Novartis Recent Developments and Future Plans
Figure 30. Boehringer Ingelheim Recent Developments and Future Plans
Figure 31. Pfizer Recent Developments and Future Plans
Figure 32. Sanofi Recent Developments and Future Plans
Figure 33. Global Blood Cancer Therapeutics Revenue Share by Players in 2020
Figure 34. Blood Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 35. Global Top 3 Players Blood Cancer Therapeutics Revenue Market Share in 2020
Figure 36. Global Top 10 Players Blood Cancer Therapeutics Revenue Market Share in 2020
Figure 37. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 38. Global Blood Cancer Therapeutics Revenue Share by Type in 2020
Figure 39. Global Blood Cancer Therapeutics Market Share Forecast by Type (2021-2026)
Figure 40. Global Blood Cancer Therapeutics Revenue Share by Application in 2020
Figure 41. Global Blood Cancer Therapeutics Market Share Forecast by Application (2021-2026)
Figure 42. North America Blood Cancer Therapeutics Sales Market Share by Type (2016-2026)
Figure 43. North America Blood Cancer Therapeutics Sales Market Share by Application (2016-2026)
Figure 44. North America Blood Cancer Therapeutics Revenue Market Share by Country (2016-2026)
Figure 45. United States Blood Cancer Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Canada Blood Cancer Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Mexico Blood Cancer Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Europe Blood Cancer Therapeutics Sales Market Share by Type (2016-2026)
Figure 49. Europe Blood Cancer Therapeutics Sales Market Share by Application (2016-2026)
Figure 50. Europe Blood Cancer Therapeutics Revenue Market Share by Country (2016-2026)
Figure 51. Germany Blood Cancer Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. France Blood Cancer Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. United Kingdom Blood Cancer Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Russia Blood Cancer Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Italy Blood Cancer Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Asia-Pacific Blood Cancer Therapeutics Sales Market Share by Type (2016-2026)
Figure 57. Asia-Pacific Blood Cancer Therapeutics Sales Market Share by Application (2016-2026)
Figure 58. Asia-Pacific Blood Cancer Therapeutics Revenue Market Share by Region (2016-2026)
Figure 59. China Blood Cancer Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Japan Blood Cancer Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. South Korea Blood Cancer Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. India Blood Cancer Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Southeast Asia Blood Cancer Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Australia Blood Cancer Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. South America Blood Cancer Therapeutics Sales Market Share by Type (2016-2026)
Figure 66. South America Blood Cancer Therapeutics Sales Market Share by Application (2016-2026)
Figure 67. South America Blood Cancer Therapeutics Revenue Market Share by Country (2016-2026)
Figure 68. Brazil Blood Cancer Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Argentina Blood Cancer Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Middle East and Africa Blood Cancer Therapeutics Sales Market Share by Type (2016-2026)
Figure 71. Middle East and Africa Blood Cancer Therapeutics Sales Market Share by Application (2016-2026)
Figure 72. Middle East and Africa Blood Cancer Therapeutics Revenue Market Share by Country (2016-2026)
Figure 73. Turkey Blood Cancer Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Saudi Arabia Blood Cancer Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. UAE Blood Cancer Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Methodology
Figure 77. Research Process and Data Source

---